[1]黎明,吴锦瑜,徐冠军,等.拉米夫定与阿德福韦酯联合治疗应答不佳的慢性乙型肝炎患者的抗病毒治疗[J].南方医科大学学报,2013,(12):1823.
点击复制

拉米夫定与阿德福韦酯联合治疗应答不佳的慢性乙型肝炎患者的抗病毒治疗()
分享到:

《南方医科大学学报》[ISSN:1673-4254/CN:44-1627/R]

卷:
期数:
2013年12期
页码:
1823
栏目:
出版日期:
2013-12-15

文章信息/Info

Title:
Therapeutic effect of antiviral regimens for chronic hepatitis B refractory to lamivudine
plus adefovir
作者:
黎明吴锦瑜徐冠军张琴陈志勇刘珍花
关键词:
肝炎乙型慢性拉米夫定阿德福韦酯恩替卡韦干扰素
Keywords:
hepatitis B chronic lamivudine adefovir dipivoxil entecavir interferon
摘要:
目的观察重组人干扰素α-2b(INFα-2b)单药治疗及恩替卡韦(ETV)与阿德福韦酯(ADV)联合治疗拉米夫定(LAM)与
ADV联合治疗应答不佳的慢性乙型肝炎患者的疗效和安全性。方法选择我院2008年6月~2011年1月LAM与ADV联合治疗
应答不佳的慢性乙型肝炎患者161例,随机分为A、B两组,A组给予INFα-2b 5×106,每周3次;B组ETV(0.5 mg,1次/d)与ADV
(10 mg,1 次/d)联合应用。所有病例治疗48 周为观察终点。采用化学发光法定量检测HBsAg和HBeAg,采用实时荧光定量
PCR检测HBV DNA水平,采用PCR产物直接测序法检测病毒耐药基因。组间比较采用配对t检验,率的比较采用χ2检验。结
果治疗48 周,A组与B 组患者血清HBV DNA水平中位数均明显下降,下降幅度分别为2.06±1.15log10 拷贝/ml 与1.77±
1.28log10 拷贝/ml;A组与B组血清病毒学应答率、血清学应答率、生化学应答率分别为:48.15%(39/81)与53.75%(43/80)、
61.70%(50/81)与53.75%(43/80)、49.38%(40/81)与60.00%(48/80),两组间差异均无统计学意义(P>0.05);基因耐药变异率分
别为30.95%(13/42)与64.86%(24/37),差异有统计学意义(P<0.05)。结论LAM联合ADV治疗应答不佳的慢性乙型肝炎患者,
选择改用INF或改用ETV与ADV联合治疗,均能获得较好的临床疗效。若患者无干扰素禁忌证,尽可能选择干扰素治疗。
Abstract:
Objective To compare the efficacy and safety of recombinant human interferon α-2b (INFα-2b) monotherapy and
combined therapy with entecavir (ETV) plus adefovir dipivoxil (ADV) in chronic hepatitis B patients with poor response to
combined therapy with lamivudine and ADV. Methods A total of 161 patients with chronic hepatitis B refractory to to
combined therapy with lamivudine (LAM) and ADV were randomized to receive INFα-2b monotherapy (5×106, three times a
week) (group A) or combined therapy with entecavir (0.5 mg/day) plus adefovir (10 mg/day) (group B). Serum levels of
HBsAg, HBeAg and HBV viral load were analyzed at 48 weeks using chemiluminescence assay and by real-time PCR as
appropriate. The drug resistance genes in HBV was tested by direct DNA sequencing. Results At 48 weeks of treatment, HBV
DNA decreased significantly in groups A and B to 2.06±1.15log10 copies/ml and 1.77±1.28log10 copies/ml, respectively. The
rates of viral response, serological response, and biochemical response in groups A and B were 48.15% (39/81) vs 53.75% (43/
80), 61.70% (50/81) vs 53.75% (43/80), and 49.38% (40/81) vs 60.00% (48/80), showing no significant differences between the two
groups (P>0.05). The drug resistance gene mutation rate was significanty higher in group B (64.86%, 24/37) than in group A
(30.95%, 13/42, P<0.05). Conclusions Chronic hepatitis B patients refractory to lamivudine combined with ADV have a good
response to INFα-2b monotherapy and combined therapy with entecavir and ADV , and interferon treatment is preferred to
reduce potential drug resistance gene mutations.

相似文献/References:

[1]邓伟,席亚明,曹长青.肝炎相关再生障碍性贫血8例临床分析[J].南方医科大学学报,2011,(08):1443.
[2]杨小云,温帆渊,吴静黎,等.慢性乙型肝炎患者血清病毒标志和丙氨酸转氨酶与肝组织病理的相关性[J].南方医科大学学报,2006,(06):892.
 YANG Xiao-yun,WEN Fan-yuan,WU Jing-li,et al.Relation of serological markers of hepatitis B virus and alanine transaminase to hepatic tissue pathology in patients with chronic hepatitis B[J].Journal of Southern Medical University,2006,(12):892.
[3]尹玉竹,谌小卫,李小毛,等.HBV宫内感染的危险因素及与HBV DNA的关系[J].南方医科大学学报,2006,(10):1452.
 YIN Yu-zhu,CHEN Xiao-wei,LI Xiao-mao,et al.Intrauterine HBV infection: risk factors and impact of HBV DNA[J].Journal of Southern Medical University,2006,(12):1452.
[4]沈建坤,周荣,王战会,等.实时荧光聚合酶链反应检测HBV基因型B~D方法的建立[J].南方医科大学学报,2005,(06):630.
 SHEN Jian-kun,ZHOU Rong,WANG Zhan-hui,et al.Establishment and application of real-time fluoriescene-based metry polymerase chain reaction for hepatitis B virus genotyping[J].Journal of Southern Medical University,2005,(12):630.
[5]魏东,张彦.12280例非感染科患者HCV抗体检测结果分析[J].南方医科大学学报,2004,(10):1125.
 WEI Dong,ZHANG Yan.Detection of HCV antibody in 12 280 inpatients admitted not for infectious diseases[J].Journal of Southern Medical University,2004,(12):1125.
[6]谢志伟,周福元,周元平.干扰素α和恩替卡韦治疗HBeAg阳性慢性乙型肝炎疗效的预测因素[J].南方医科大学学报,2013,(06):878.
[7]张磊,范志娟,康华,等.HPLC/MS分析乙肝相关性肝细胞癌的血清代谢轮廓分析[J].南方医科大学学报,2019,(01):49.[doi:10.12122/j.issn.1673-4254.2019.01.08]
[8]施斌斌,彭劼,温帆渊,等.百赛诺对慢性乙型肝炎患者细胞免疫应答的影响[J].南方医科大学学报,2005,(06):706.
 SHI Bin-bin,PENG Jie,WEN Fan-yuan,et al.Effect of bicyclol tablets on cellular immune responses in patients with chronic hepatitis B[J].Journal of Southern Medical University,2005,(12):706.
[9]库热西江·托呼提,哈木拉提·吾甫尔,张利占,等.和田地区维吾尔族、汉族人群HBsAg携带率的流行病学调查分析[J].南方医科大学学报,2004,(11):1287.
 Kurexijiang Tuohuti,Hamulati Wufuer,ZHANG Li-zhan,et al.Epidemiological survey of HBsAg carriers in the Uighur and Han populations in the Khotan Area of Xinjiang Autonomous Region[J].Journal of Southern Medical University,2004,(12):1287.
[10]余雪平,郭如意,柯邵鹏,等.慢性乙型肝炎及其肝硬化患者HBsAg与HBV DNA定量变化及其相关性[J].南方医科大学学报,2015,(05):682.

更新日期/Last Update: 1900-01-01